{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-116764","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.811875+00:00","generated_at":"2026-05-16T15:54:54.682119+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Citius Oncology launches LYMPHIR, first commercial product, for CTCL","bullets":["LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.","Phase 3 pivotal study: 36.2% ORR, median time to response 1.4 months, no cumulative toxicity.","Entering U.S. market estimated >$400M; permanent J-code J9161 and NCCN Category 2A inclusion.","Ex-U.S. distribution pact with Integris Pharma for 12 Southern European/Balkan markets.","Company holds exclusive rights to all markets except India, Japan, and parts of Asia."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-116764","json":"https://secwatch.observer/filing/0001213900-25-116764.json","markdown":"https://secwatch.observer/filing/0001213900-25-116764.md","text":"https://secwatch.observer/filing/0001213900-25-116764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/0001213900-25-116764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea0267560-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:54:54.682119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}